A Phase 2 bone marrow transplant trial in SCD patients using haploidentical donors and lower intensity conditioning had high ...

Patients, aged between 12 and 35 years, received a single dose of intravenous exa-cel for 2 to 7 days following myeloablative ...

For almost all patients with sickle cell disease, treatment with exagamglogene autotemcel (exa-cel) eliminates vaso-occlusive ...

According to Courtney Rice, Principal at Acadia Strategy Partners, both exa-cel and lovo-cel rely on a myeloablative busulfan conditioning regimen to prepare patients for infusion. This ...

Casgevy’s safety profile is consistent with the current standard of care for the two diseases namely, myeloablative conditioning with busulfan and haematopoietic stem cell transplant.

CD34+ HSPCs were edited with the use of CRISPR-Cas9. Before the exa-cel infusion, patients underwent myeloablative conditioning with pharmacokinetically dose-adjusted busulfan. The primary end ...

The safety profile of exa-cel was generally consistent with that of myeloablative busulfan conditioning and autologous HSPC transplantation. No deaths or cancers occurred. A data sharing statement ...

Clinical trial holds delay therapies getting to market and may be on the rise in oncology. But there's a lot the public doesn ...

prophylaxis in patients with hematologic malignancies receiving myeloablative conditioning (MAC). When compared to the historical PTCy cohort in this patient population, Orca-T offered potentially ...

Using our standard regimen (non-myeloablative total body irradiation, thymic irradiation, anti-thymocyte globulin, donor bone marrow infusion and a 1-month course of cyclosporine), we found no ...

This clinical hold was placed by the FDA last December following a grade 5 (fatal) adverse effect, potentially related to the non-myeloablative lymphodepletion pre-conditioning regimen observed in ...